First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction

Chafetz, Ilana; Kuhnreich, Ido; Sammar, Marei; Tal, Yossi; Gibor, Yair; Meiri, Hamutal; Cuckle, Howard; Wolf, Myles

doi:10.1016/j.ajog.2007.02.025

Cited by 195 publications

(138 citation statements)

References 38 publications

Supporting

Mentioning

117

Contrasting

Unclassified

Order By: Relevance

“…[7][8][9][10][11][12][13][14][15] However, less remarkable predictive properties have been reported in recent studies, with some describing a potential role of PP13 levels for predicting preeclampsia or small for gestational age (SGA) in combination with other biomarkers. [9,12,15] Variation in study design, population characteristics, numbers of cases and reporting of the diagnostic accuracy of PP13, have made it difficult to interpret the clinical significance of these results.…”

Section: Introductionmentioning

confidence: 99%

First trimester screening of maternal placental protein 13 for predicting preeclampsia and small for gestational age: In-house study and systematic review

et al. 2012

View full text Add to dashboard Cite

Objective: To describe normative levels of PP13 in first-trimester of pregnancy and determine the accuracy of PP13 in predicting preeclampsia and small for gestational age (SGA) infants.Methods: We measured PP13 in archived first trimester serum samples from an unselected maternal cohort of 2,989 women. Associations of PP13 levels and diagnostic accuracy in predicting adverse pregnancy outcomes were assessed using multivariate logistic regression models. Due to inadequate number of cases we then conducted a systematic review involving structured search of electronic databases and subsequent meta-analysis of predictive accuracy using data from similar studies.Results: Overall, 2,678 women were included in the in-house study with 71 (2.7%) preeclampsia cases, 5 (0.2%) early-onset preeclampsia (≤34 weeks) cases; and 191 (7.1%) and 41 (1.5%) infants SGA<10 th and <3 rd centile. Median (IQR) normative level of PP13 in unaffected pregnancies was 53.5 (37.7-71.8) pg/ml. The area under the receiver operating characteristic curve (AUC) for multivariate models was 0.72 (95%CI 0.66-0.78) for preeclampsia; 0.82 (95%CI 0.63-0.99) for early-onset preeclampsia; 0.73 (95%CI 0.69-0.77) for SGA<10 th centile; and 0.83 (95%CI 0.78-0.88) for SGA<3 rd centile. Eight studies were included in the systematic review, normative levels of PP13 was assessed in four studies but these were variable; and meta-analysis was performed on seven studies. Sensitivity rates of PP13 based on 5% fixed false positive rates were 24%, 45% and 26% for preeclampsia, for early-onset preeclampsia and SGA, respectively.Conclusions: First-trimester PP13, in combination with maternal characteristics and other serum biomarkers was inadequate for screening purposes and predicting women at risk.

show abstract

Section: Introductionmentioning

confidence: 99%

First trimester screening of maternal placental protein 13 for predicting preeclampsia and small for gestational age: In-house study and systematic review

et al. 2012

View full text Add to dashboard Cite

show abstract

“…The levels of PP-13 in serum gradually increase in normal pregnancy, but abnormally low levels of PP-13 were detected in first trimester serum samples of women who subsequently developed preeclampsia and IUGR [26]. Furthermore, it was reported that first-trimester serum PP-13 levels may serve as a marker for early onset PE (before 34 weeks of gestation) only, but not for severe PE [27]. Combined measuring of maternal serum PP-13 and median uterine artery pulsatility index by using ultrasound early in pregnancy seems to predict severe PE [25].…”

Section: Immunological Markers Placental Protein 13 (Pp-13)mentioning

confidence: 99%

Role of Biomarkers in Early Detection of Preeclampsia

Kar¹

2014

JCDR

View full text Add to dashboard Cite

“…Nine studies provided data on cervicovaginal phosphorylated insulin-like growth factor binding protein-1 (phI-GFBP-1), [65][66][67]69,[72][73][74]77,79 seven studies provided data on relaxin, 34,60,61,70,71,75,78 three studies provided data on cervicovaginal human chorionic gonadotrophin (hCG), 63,68,76 two studies provided data on cervicovaginal prolactin, 62,64 four studies provided data on pregnancy-associated plasma protein-A (PAPP-A), 81,84,85,87 two studies provided data on activin-A, 80,82 and one study each provided data on placental protein-13 (PP13) 83 and pregnancy-specific-b1 glycoprotein (SP1). 86 For cervicovaginal levels of hCG, phIGFBP-1, and prolactin, the pooled sensitivities, specificities, positive and negative LRs to predict preterm birth before 32, 34, and 37 weeks of gestation ranged between 33 and 83% (median, 67%), 62 and 97% (median, 79%), 1.6 and 19.0 (median, 3.2), and 0.2 and 0.8 (median, 0.5), respectively (Table 1).…”

Section: Placental Protein/hormone-related Biomarkersmentioning

confidence: 99%

Novel biomarkers for the prediction of the spontaneous preterm birth phenotype: a systematic review and meta-analysis

Conde-Agudelo

Papageorghiou

Kennedy

et al. 2011

BJOG: An International Journal of Obstetrics &Amp; Gynaecology

147

114

View full text Add to dashboard Cite

Background Being able to predict preterm birth is important, as it may allow a high-risk population to be selected for future interventional studies and help in understanding the pathways that lead to preterm birth.Objective To investigate the accuracy of novel biomarkers to predict spontaneous preterm birth in women with singleton pregnancies and no symptoms of preterm labour.Search strategy Electronic searches in PubMed, Embase, Cinahl, Lilacs, and Medion, references of retrieved articles, and conference proceedings. No language restrictions were applied.Selection criteria Observational studies that evaluated the accuracy of biomarkers proposed in the last decade to predict spontaneous preterm birth in asymptomatic women. We excluded studies in which biomarkers were evaluated in women with preterm labour.Data collection and analysis Two reviewers independently extracted data on study characteristics, quality, and accuracy. Data were arranged in 2 · 2 contingency tables and synthesised separately for spontaneous preterm birth before 32, 34, and 37 weeks of gestation. We used bivariate meta-analysis to estimate pooled sensitivities and specificities, and calculated likelihood ratios (LRs).Main results A total of 72 studies, including 89 786 women and evaluating 30 novel biomarkers, met the inclusion criteria. Only three biomarkers (proteome profile and prolactin in cervicovaginal fluid, and matrix metalloproteinase-8 in amniotic fluid) had positive LRs > 10. However, each of these biomarkers was evaluated in only one small study. Four biomarkers had a moderate predictive accuracy (interleukin-6 and angiogenin, in amniotic fluid; human chorionic gonadotrophin and phosphorylated insulin-like growth factor binding protein-1, in cervicovaginal fluid). The remaining biomarkers had low predictive accuracies.Conclusions None of the biomarkers evaluated in this review meet the criteria to be considered a clinically useful test to predict spontaneous preterm birth. Further large, prospective cohort studies are needed to evaluate promising biomarkers such as a proteome profile in cervicovaginal fluid.

show abstract

First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction

Cited by 195 publications

References 38 publications

First trimester screening of maternal placental protein 13 for predicting preeclampsia and small for gestational age: In-house study and systematic review

First trimester screening of maternal placental protein 13 for predicting preeclampsia and small for gestational age: In-house study and systematic review

Role of Biomarkers in Early Detection of Preeclampsia

Novel biomarkers for the prediction of the spontaneous preterm birth phenotype: a systematic review and meta-analysis

Contact Info

Product

Resources

About